Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C

[Guest guest]

http://www.ingentaconnect.com/content/fm/fmb/2008/00000003/00000005/art00010;jse\

ssionid=n3h3nohltkl9.alice

Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C

Authors: Rossignol, Jean-François; Keeffe, Emmet B

Source: Future Microbiology, Volume 3, Number 5, October 2008 , pp. 539-545(7)

Publisher: Future Medicine

Abstract:

Nitazoxanide, the first thiazolide, was originally developed for the treatment

of Cryptosporidium parvum. The antiviral activity of nitazoxanide was discovered

by serendipity in patients with AIDS who were treated for cryptosporidial

diarrhea and had HBV or HCV co-infection. In preliminary open-label studies of

patients with chronic hepatitis B, nitazoxanide suppressed serum HBV DNA and led

to loss or seroconversion of hepatitis B e antigen in the majority of patients,

as well as hepatitis B surface antigen in approximately a quarter of patients.

In Phase II studies of patients with chronic hepatitis C genotype 4,

nitazoxanide combined with peginterferon alfa-2a, with or without ribavirin,

increased the sustained virologic response rate to 79-80 versus 50% with

peginterferon plus ribavirin standard of care. Randomized, controlled studies of

naive and nonresponder patients with chronic hepatitis C genotype 1 and patients

with chronic hepatitis B are underway, and new second generation thiazolides are

being developed.

Keywords: chronic hepatitis B; chronic hepatitis C; eukaryotic initiation factor

2α phosphorylation; HBV; HCV; interferon; nitazoxanide; peginterferon; protein

kinase RNA-activated phosphorylation; ribavirin; thiazolides

Document Type: Research article

DOI: 10.2217/17460913.3.5.539

[Guest guest]

http://www.ingentaconnect.com/content/fm/fmb/2008/00000003/00000005/art00010;jse\

ssionid=n3h3nohltkl9.alice

Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and C

Authors: Rossignol, Jean-François; Keeffe, Emmet B

Source: Future Microbiology, Volume 3, Number 5, October 2008 , pp. 539-545(7)

Publisher: Future Medicine

Abstract:

Nitazoxanide, the first thiazolide, was originally developed for the treatment

of Cryptosporidium parvum. The antiviral activity of nitazoxanide was discovered

by serendipity in patients with AIDS who were treated for cryptosporidial

diarrhea and had HBV or HCV co-infection. In preliminary open-label studies of

patients with chronic hepatitis B, nitazoxanide suppressed serum HBV DNA and led

to loss or seroconversion of hepatitis B e antigen in the majority of patients,

as well as hepatitis B surface antigen in approximately a quarter of patients.

In Phase II studies of patients with chronic hepatitis C genotype 4,

nitazoxanide combined with peginterferon alfa-2a, with or without ribavirin,

increased the sustained virologic response rate to 79-80 versus 50% with

peginterferon plus ribavirin standard of care. Randomized, controlled studies of

naive and nonresponder patients with chronic hepatitis C genotype 1 and patients

with chronic hepatitis B are underway, and new second generation thiazolides are

being developed.

Keywords: chronic hepatitis B; chronic hepatitis C; eukaryotic initiation factor

2α phosphorylation; HBV; HCV; interferon; nitazoxanide; peginterferon; protein

kinase RNA-activated phosphorylation; ribavirin; thiazolides

Document Type: Research article

DOI: 10.2217/17460913.3.5.539